title: The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats.
abstract: Clinical studies indicate a nephro-protective effect in conjunction with the use of ACE inhibitors. This study's aim was to determine whether ACE inhibitors influence the metabolism of glomerular cells in addition to their known hemodynamic effects. Streptozotocin diabetic rats were treated with lisinopril (DLis 1.5 mg/l water), or hydralazine (Dhyd, 50 mg/l water) over 4 weeks. Untreated diabetic rats (DC) and non-diabetic rats (C) served as controls. After four weeks of treatment, urinary excretion of albumin, blood pressure and metabolic control (Glyc-Hb) were measured. After treatment glomeruli were isolated and homogenized, and beta-NAG and total proteolytic activity against azocasein were measured. Glycated hemoglobin levels were similar in all diabetic groups (DC, 12%, Dhyd, 10%; DLis 11%). Blood pressure of DLis rats (79 +/- 3 mmHg) and DHyd rats (46 +/- 2 mmHg) was lower than that of DC rats (111 +/- 3 mmHg). Urinary albumin excretion of diabetic groups was lowest in DLis. Diabetic rats showed a decrease in glomerular beta-NAG (10 vs. 60.5 U/g protein) and total proteolytic activity against azocasein (148 vs. 170 U/mg protein hour) compared to non-diabetic rats. Lisinopril increased beta-NAG (30 vs. 14 U/g protein) and total proteolytic activity (160.5 vs. 141.5 U/mg protein hour) compared with hydralazine. Our study confirms that the nephro-protective effect of ACE inhibitors is partially due to modulatory effects on the metabolism of basement membrane proteins.
authors.affiliation: Department of Internal Medicine, St. Josef Hospital, Landhausstrasse 25, D-69115 Heidelberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Koenen
authors.forename: C
authors.initials: C
authors.lastname: Lang
authors.forename: H P
authors.initials: HP
authors.lastname: Kempe
authors.forename: E
authors.initials: E
authors.lastname: Werle
authors.forename: C
authors.initials: C
authors.lastname: Hasslacher
mesh_terms: D000118:Acetylglucosaminidase / Q000378:metabolism*; D000419:Albuminuria; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology* / Q000503:physiopathology; D010450:Endopeptidases / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006830:Hydralazine / Q000494:pharmacology*; D007678:Kidney Glomerulus / Q000187:drug effects / Q000201:enzymology*; D017706:Lisinopril / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values
chemical_list: D000118:Acetylglucosaminidase; D000806:Angiotensin-Converting Enzyme Inhibitors; D010450:Endopeptidases; D006442:Glycated Hemoglobin; D006830:Hydralazine; D017706:Lisinopril